National Research (NRCIA) vs. Pieris Pharmaceuticals (PIRS) Critical Contrast
National Research (NASDAQ: NRCIA) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
This is a summary of recent ratings and target prices for National Research and Pieris Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares National Research and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
National Research has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.
Insider & Institutional Ownership
33.6% of National Research shares are held by institutional investors. Comparatively, 44.0% of Pieris Pharmaceuticals shares are held by institutional investors. 5.7% of National Research shares are held by insiders. Comparatively, 4.1% of Pieris Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares National Research and Pieris Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|National Research||$117.56 million||6.99||$22.94 million||$0.58||57.84|
|Pieris Pharmaceuticals||$25.27 million||13.98||-$17.64 million||($0.40)||-16.40|
National Research has higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.
National Research pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. Pieris Pharmaceuticals does not pay a dividend. National Research pays out 69.0% of its earnings in the form of a dividend.
National Research beats Pieris Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About National Research
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience, satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The company offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. It also provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. The company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, increase patient satisfaction and support safe care transitions; and risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. It provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems and post-acute providers, such as home health, long term care, hospice, and payer organizations. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.